Less than a tenth of people that would benefit from weight-loss injections such as Wegovy are able to get them, caution the World Health Organization as it issues its first guidance on the therapies.
Considering over a billion people worldwide currently obese, it is calling for increased and just access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be treated with thorough and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key barriers to widespread access to the injections that can assist patients in reducing considerable weight, explains the agency.
GLP-1 Therapy Supply Crisis
Despite the present most optimistic case, the manufacturing of these medications might only reach around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The recommendation urges governments and firms to expand access, via strategies including patent sharing.
The intellectual property rights on the active ingredient – the core component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Obesity Jabs Operate
GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and boost feelings of fullness so people reduce food intake.
People commonly begin shedding pounds in the initial weeks of beginning the regular doses.
Evidence indicates patients may see weight return within a year of stopping the treatment, as their usual appetite come back.
To be carrying excess weight raises your chance for contracting health problems, like diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
